Theseus Pharmaceuticals Inc (DELISTED) (THRX:DL)
4.06
0.00 (0.00%)
USD |
NASDAQ |
Feb 23, 16:00
Theseus Pharmaceuticals Research and Development Expense (Quarterly): 11.52M for Sept. 30, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 11.52M |
| June 30, 2023 | 12.92M |
| March 31, 2023 | 12.40M |
| December 31, 2022 | 10.38M |
| September 30, 2022 | 11.42M |
| June 30, 2022 | 7.344M |
| March 31, 2022 | 6.548M |
| Date | Value |
|---|---|
| December 31, 2021 | 5.022M |
| September 30, 2021 | 4.996M |
| June 30, 2021 | 4.485M |
| March 31, 2021 | 3.825M |
| December 31, 2020 | 2.488M |
| September 30, 2020 | 1.275M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.275M
Minimum
Sep 2020
12.92M
Maximum
Jun 2023
7.279M
Average
6.548M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| Karuna Therapeutics Inc (DELISTED) | 82.19M |
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 7.160M |
| iBio Inc | 1.535M |
| Theriva Biologics Inc | 3.459M |